Location History:
- Traunreut, DE (2017)
- Munich, DE (2020 - 2023)
Company Filing History:
Years Active: 2017-2023
Title: Innovations by Inventor Sabine Rauth in Munich
Introduction
Sabine Rauth is an innovative inventor based in Munich, Germany. With a total of three patents to her name, she has made significant contributions to the field of biochemistry through her pioneering work on human lipocalin 2 (Lcn2/hNGAL).
Latest Patents
One of her latest patents focuses on "Muteins of human lipocalin 2 (Lcn2, hNGAL) with affinity for a given target." This invention introduces a novel library aimed at generating muteins derived from human lipocalin 2. These muteins bind to specific targets with detectable affinity, providing potential applications in medical research and treatment. Notably, they may be used to bind and deplete pathological biomolecules such as the amyloid beta peptide, which is linked to Alzheimer's disease. The patent also details methods for producing these muteins, indicating their extensive utility in therapeutic settings.
Career Highlights
Sabine Rauth is currently associated with Pieris Pharmaceuticals GmbH, a company devoted to the advancement of therapeutic pharmaceuticals. Her work is characterized by a strong emphasis on the intersection of biochemistry and medical applications, highlighting her commitment to translating scientific research into viable health solutions.
Collaborations
Throughout her career, Rauth has collaborated with other notable researchers, including Arne Skerra and Michaela Gebauer. These collaborations have further enriched her research, contributing to advancements in the methodologies for generating therapeutic agents derived from lipocalin 2.
Conclusion
In summary, Sabine Rauth is an influential inventor making strides in the field of biochemistry. Her work with human lipocalin 2 and the development of muteins has the potential to significantly impact the treatment of diseases such as Alzheimer's and cancer. As her career progresses, it will be exciting to see how her innovations continue to shape the landscape of medical research and therapeutic development.